SEQUUS DOXIL FOR AIDS-RELATED KAPOSI's SARCOMA GAINS ACCELERATED APPROVAL NOV. 17; STUDIES IN BREAST, OVARIAN AND LIVER SOLID TUMORS ARE UNDER WAY
Executive Summary
Sequus' Doxil (liposomal doxorubicin) is indicated "for the treatment of Kaposi's sarcoma in AIDS patients with disease that has progressed on prior combination therapy or in patients who are intolerant to such therapy," FDA's Nov. 17 approval letter states.